Sofia Aakko
Helsinki, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs.
Journal: Expert review of anticancer therapy
Published: February 28, 2026
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.
Journal: The Lancet. Haematology
Published: December 15, 2024
CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies.
Journal: Scientific reports
Published: November 16, 2024
Personalizing precision medicine: Patients with AML perceptions about treatment decisions.
Journal: Patient education and counseling
Published: October 13, 2022
Targeting DNA Homologous Repair Proficiency With Concomitant Topoisomerase II and c-Abl Inhibition.
Journal: Frontiers in oncology
Published: June 30, 2021
MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells.
Journal: Translational oncology
Published: September 25, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026